[{"id":"e41df1b0-a381-4409-acf3-86d752328c66","acronym":"","url":"https://clinicaltrials.gov/study/NCT07472933","created_at":"2026-03-28T01:36:46.537Z","updated_at":"2026-03-28T01:36:46.537Z","phase":"Phase 2","brief_title":"Vebotolimab Combined With Ptorlimab for EGFR-positive Refractory Advanced Biliary Tract Malignancies","source_id_and_acronym":"NCT07472933","lead_sponsor":"West China Hospital","biomarkers":" EGFR","pipe":"","alterations":" ","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Loqtorzi (toripalimab-tpzi) • Tevimbra (tislelizumab-jsgr)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 44","initiation":"Initiation: 04/01/2026","start_date":" 04/01/2026","primary_txt":" Primary completion: 02/29/2028","primary_completion_date":" 02/29/2028","study_txt":" Completion: 02/29/2028","study_completion_date":" 02/29/2028","last_update_posted":"2026-03-18"},{"id":"88f3eaef-14f2-44c3-90f7-c4ebafee84e8","acronym":"","url":"https://clinicaltrials.gov/study/NCT07474064","created_at":"2026-03-28T01:40:03.816Z","updated_at":"2026-03-28T01:40:03.816Z","phase":"Phase 2","brief_title":"Probiotics Combined With Targeted Therapy Plus Immunotherapy in Bladder-Preserving Setting for Patients With MIBC","source_id_and_acronym":"NCT07474064","lead_sponsor":"chenxu","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Loqtorzi (toripalimab-tpzi) • Aidixi (disitamab vedotin) • Cdactin-O (CBM588)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 146","initiation":"Initiation: 03/26/2026","start_date":" 03/26/2026","primary_txt":" Primary completion: 03/31/2031","primary_completion_date":" 03/31/2031","study_txt":" Completion: 03/31/2035","study_completion_date":" 03/31/2035","last_update_posted":"2026-03-17"},{"id":"cc4251d0-e106-4faa-b5dd-5c8373253473","acronym":"","url":"https://clinicaltrials.gov/study/NCT06940180","created_at":"2025-06-28T13:40:14.934Z","updated_at":"2025-06-28T13:40:14.934Z","phase":"Phase 2","brief_title":"Toripalimab With Chemotherapy for Sinus Cancer","source_id_and_acronym":"NCT06940180","lead_sponsor":"Glenn J. Hanna","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • docetaxel • Loqtorzi (toripalimab-tpzi)"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 06/17/2025","start_date":" 06/17/2025","primary_txt":" Primary completion: 02/01/2028","primary_completion_date":" 02/01/2028","study_txt":" Completion: 02/01/2029","study_completion_date":" 02/01/2029","last_update_posted":"2025-06-26"},{"id":"1f0aec53-2934-4132-a061-58ff65518298","acronym":"","url":"https://clinicaltrials.gov/study/NCT06984588","created_at":"2025-09-07T01:41:15.296Z","updated_at":"2025-09-07T01:41:15.296Z","phase":"Phase 2/3","brief_title":"A Study to Compare Uliledlimab Combined With Toripalimab, Toripalimab Monotherapy, and Pembrolizumab Monotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1- and CD73- Selected Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT06984588","lead_sponsor":"TJ Biopharma Co., Ltd.","biomarkers":" PD-L1 • BRAF","pipe":"","alterations":" ","tags":["PD-L1 • BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Loqtorzi (toripalimab-tpzi) • uliledlimab (TJD5)"],"overall_status":"Recruiting","enrollment":" Enrollment 450","initiation":"Initiation: 03/28/2024","start_date":" 03/28/2024","primary_txt":" Primary completion: 08/05/2028","primary_completion_date":" 08/05/2028","study_txt":" Completion: 09/30/2028","study_completion_date":" 09/30/2028","last_update_posted":"2025-05-22"},{"id":"8100f49e-ecbc-41b2-9130-5ed625da8fc7","acronym":"","url":"https://clinicaltrials.gov/study/NCT04669496","created_at":"2025-02-25T13:40:17.235Z","updated_at":"2025-02-25T13:40:17.235Z","phase":"Phase 2/3","brief_title":"Phase II-III Clinical Trial of PD1 Antibody (Toripalimab), Lenvatinib and GEMOX Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma with High-risk Recurrence Factors","source_id_and_acronym":"NCT04669496","lead_sponsor":"Shanghai Zhongshan Hospital","biomarkers":" TMB • MSI • CEACAM5 • MUC16","pipe":" | ","alterations":" PD-L1 expression","tags":["TMB • MSI • CEACAM5 • MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lenvima (lenvatinib) • Loqtorzi (toripalimab-tpzi) • oxaliplatin"],"overall_status":"Recruiting","enrollment":" Enrollment 178","initiation":"Initiation: 01/20/2021","start_date":" 01/20/2021","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2025-02-21"},{"id":"102a276a-2e7a-4a7f-a75b-c71813873058","acronym":"JS001-027-III-HCC","url":"https://clinicaltrials.gov/study/NCT04523493","created_at":"2021-01-18T21:40:02.000Z","updated_at":"2025-02-25T14:02:00.920Z","phase":"Phase 3","brief_title":"Phase III Study of Toripalimab（JS001） Combined With Lenvatinib for Advanced HCC","source_id_and_acronym":"NCT04523493 - JS001-027-III-HCC","lead_sponsor":"Shanghai Junshi Bioscience Co., Ltd.","biomarkers":" PD-L1 • TMB","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1 • TMB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lenvima (lenvatinib) • Loqtorzi (toripalimab-tpzi)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 530","initiation":"Initiation: 06/29/2020","start_date":" 06/29/2020","primary_txt":" Primary completion: 05/31/2025","primary_completion_date":" 05/31/2025","study_txt":" Completion: 09/01/2026","study_completion_date":" 09/01/2026","last_update_posted":"2025-02-19"},{"id":"45785a07-9d38-4987-a49f-4d7f22463b54","acronym":"","url":"https://clinicaltrials.gov/study/NCT05188664","created_at":"2022-01-12T14:53:34.539Z","updated_at":"2025-02-25T14:08:34.404Z","phase":"Phase 1/2","brief_title":"Study of LaNova Medicines(LM)-302 in Combination With Toripalimab in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT05188664","lead_sponsor":"LaNova Australia Pty Limited","biomarkers":" CLDN18","pipe":"","alterations":" ","tags":["CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Loqtorzi (toripalimab-tpzi) • tecotabart vedotin (LM-302)"],"overall_status":"Completed","enrollment":" Enrollment 20","initiation":"Initiation: 05/10/2022","start_date":" 05/10/2022","primary_txt":" Primary completion: 11/14/2023","primary_completion_date":" 11/14/2023","study_txt":" Completion: 11/14/2023","study_completion_date":" 11/14/2023","last_update_posted":"2025-02-17"},{"id":"b9c34573-0235-40cd-9198-16fe6c36e675","acronym":"HBCH-RT-2021-01","url":"https://clinicaltrials.gov/study/NCT05021328","created_at":"2021-08-25T14:53:25.228Z","updated_at":"2025-02-25T16:32:34.697Z","phase":"Phase 1","brief_title":"Toripalimab Combined With Anlotinib and SBRT in Patients With Untreated Brain Metastases of Driven Gene-negative NSCLC","source_id_and_acronym":"NCT05021328 - HBCH-RT-2021-01","lead_sponsor":"Hubei Cancer Hospital","biomarkers":" EGFR • ALK • ROS1","pipe":"","alterations":" ","tags":["EGFR • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Focus V (anlotinib) • Loqtorzi (toripalimab-tpzi)"],"overall_status":"Completed","enrollment":" Enrollment 13","initiation":"Initiation: 10/01/2021","start_date":" 10/01/2021","primary_txt":" Primary completion: 02/05/2025","primary_completion_date":" 02/05/2025","study_txt":" Completion: 02/05/2025","study_completion_date":" 02/05/2025","last_update_posted":"2025-02-07"},{"id":"bb8c9bbf-af0e-4c45-9940-af8cc5fdbc47","acronym":"PNACGEC","url":"https://clinicaltrials.gov/study/NCT05033392","created_at":"2021-09-02T14:53:11.733Z","updated_at":"2025-02-25T16:45:35.071Z","phase":"Phase 2","brief_title":"PD-1 Blockade With JS001 Plus Neoadjuvant Chemotherapy for Gastric/Gastroesophageal Junction Cancer","source_id_and_acronym":"NCT05033392 - PNACGEC","lead_sponsor":"Wan He","biomarkers":" PD-L1 • MSI","pipe":" | ","alterations":" MSI-H/dMMR","tags":["PD-L1 • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Loqtorzi (toripalimab-tpzi)"],"overall_status":"Recruiting","enrollment":" Enrollment 62","initiation":"Initiation: 09/14/2021","start_date":" 09/14/2021","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2025-02-05"},{"id":"b1bfb829-6051-48a2-8e1d-95a6b089f5de","acronym":"","url":"https://clinicaltrials.gov/study/NCT06038396","created_at":"2023-09-14T14:13:03.466Z","updated_at":"2025-02-25T17:39:19.635Z","phase":"Phase 1/2","brief_title":"A Study of RC118 Plus Toripalimab / RC148 in Patients with Locally Advanced Unresectable or Metastatic Solid Tumors","source_id_and_acronym":"NCT06038396","lead_sponsor":"RemeGen Co., Ltd.","biomarkers":" CLDN18","pipe":" | ","alterations":" CLDN1 positive","tags":["CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CLDN1 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Loqtorzi (toripalimab-tpzi) • Aidixi (disitamab vedotin) • ciletatug vedotin (RC118)"],"overall_status":"Recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 08/03/2023","start_date":" 08/03/2023","primary_txt":" Primary completion: 02/28/2026","primary_completion_date":" 02/28/2026","study_txt":" Completion: 08/31/2026","study_completion_date":" 08/31/2026","last_update_posted":"2025-01-29"},{"id":"9d739726-be1b-490e-bc9a-406b8d4333a4","acronym":"NEOTORCH-BREAST01","url":"https://clinicaltrials.gov/study/NCT06611813","created_at":"2025-02-26T14:56:34.715Z","updated_at":"2025-02-26T14:56:34.715Z","phase":"Phase 2","brief_title":"Neoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer (NEOTORCH-BREAST01)","source_id_and_acronym":"NCT06611813 - NEOTORCH-BREAST01","lead_sponsor":"First Affiliated Hospital of Zhejiang University","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • Loqtorzi (toripalimab-tpzi) • cyclophosphamide • epirubicin"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 06/11/2024","start_date":" 06/11/2024","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 06/01/2029","study_completion_date":" 06/01/2029","last_update_posted":"2024-11-15"},{"id":"70cf91ce-5494-4e3c-8936-16d7a4476273","acronym":"TORCH-R","url":"https://clinicaltrials.gov/study/NCT05628038","created_at":"2025-03-03T11:15:37.220Z","updated_at":"2025-03-03T11:15:37.220Z","phase":"Phase 2","brief_title":"The Combination of Hypofractionated Radiotherapy and Immunotherapy in Locally Recurrent Rectal Cancer","source_id_and_acronym":"NCT05628038 - TORCH-R","lead_sponsor":"Fudan University","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Erbitux (cetuximab) • 5-fluorouracil • Loqtorzi (toripalimab-tpzi) • capecitabine • oxaliplatin • irinotecan • leucovorin calcium • Tomudex (raltitrexed)"],"overall_status":"Recruiting","enrollment":" Enrollment 93","initiation":"Initiation: 11/30/2022","start_date":" 11/30/2022","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-10-01"},{"id":"49f10be5-e581-4336-adcb-8f654d6db98e","acronym":"","url":"https://clinicaltrials.gov/study/NCT06547203","created_at":"2025-02-27T08:04:34.471Z","updated_at":"2025-02-27T08:04:34.471Z","phase":"Phase 2","brief_title":"Cetuximab, Irinotecan, Toripalimab in RAS/BRAF Wild-type Ultraselected Right-sided Colorectal Cancer Study","source_id_and_acronym":"NCT06547203","lead_sponsor":"Sun Yat-sen University","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • Loqtorzi (toripalimab-tpzi) • irinotecan"],"overall_status":"Recruiting","enrollment":" Enrollment 34","initiation":"Initiation: 07/18/2024","start_date":" 07/18/2024","primary_txt":" Primary completion: 07/30/2026","primary_completion_date":" 07/30/2026","study_txt":" Completion: 07/30/2029","study_completion_date":" 07/30/2029","last_update_posted":"2024-08-09"},{"id":"704f4150-632c-42b3-b43a-c894f610bde3","acronym":"","url":"https://clinicaltrials.gov/study/NCT06525428","created_at":"2025-02-27T07:56:08.478Z","updated_at":"2025-02-27T07:56:08.478Z","phase":"Phase 2","brief_title":"Standard Systemic Therapy Combined With High/Low-dose Radiotherapy Plus Toripalimab for Metastatic Colorectal Cancer","source_id_and_acronym":"NCT06525428","lead_sponsor":"Fudan University","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Erbitux (cetuximab) • 5-fluorouracil • Loqtorzi (toripalimab-tpzi) • capecitabine • oxaliplatin • irinotecan"],"overall_status":"Recruiting","enrollment":" Enrollment 96","initiation":"Initiation: 04/01/2024","start_date":" 04/01/2024","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 12/01/2027","study_completion_date":" 12/01/2027","last_update_posted":"2024-07-29"},{"id":"1532ca3a-2502-4dd2-b1ac-69ae84a9d9a0","acronym":"","url":"https://clinicaltrials.gov/study/NCT04785196","created_at":"2021-03-05T12:55:16.352Z","updated_at":"2024-07-02T16:34:37.707Z","phase":"Phase 1/2","brief_title":"APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid Tumors","source_id_and_acronym":"NCT04785196","lead_sponsor":"Ascentage Pharma Group Inc.","biomarkers":" TP53 • MDM2","pipe":" | ","alterations":" MDM2 amplification","tags":["TP53 • MDM2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MDM2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Loqtorzi (toripalimab-tpzi) • alrizomadlin (APG-115)"],"overall_status":"Recruiting","enrollment":" Enrollment 95","initiation":"Initiation: 05/26/2021","start_date":" 05/26/2021","primary_txt":" Primary completion: 04/01/2026","primary_completion_date":" 04/01/2026","study_txt":" Completion: 01/01/2027","study_completion_date":" 01/01/2027","last_update_posted":"2024-06-06"},{"id":"5f362e7b-9d6f-4352-816b-b51797aaa0ba","acronym":"neoR-TORCH","url":"https://clinicaltrials.gov/study/NCT06437977","created_at":"2024-06-01T04:13:22.227Z","updated_at":"2024-07-02T16:34:59.769Z","phase":"Phase 3","brief_title":"Neoadjuvant Therapy of SBRT Sequencial With Toripalimab and Chemotherapy in Resectable Stage II-III NSCLC Patients(neoR-TORCH)","source_id_and_acronym":"NCT06437977 - neoR-TORCH","lead_sponsor":"Shanghai Chest Hospital","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • paclitaxel • docetaxel • Loqtorzi (toripalimab-tpzi)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 478","initiation":"Initiation: 06/01/2024","start_date":" 06/01/2024","primary_txt":" Primary completion: 06/01/2027","primary_completion_date":" 06/01/2027","study_txt":" Completion: 06/01/2029","study_completion_date":" 06/01/2029","last_update_posted":"2024-05-31"},{"id":"641e1e85-802d-456b-8ede-12ae69c97226","acronym":"NeoTENNIS","url":"https://clinicaltrials.gov/study/NCT04418154","created_at":"2021-01-18T21:17:40.275Z","updated_at":"2024-07-02T16:35:02.194Z","phase":"Phase 2","brief_title":"Neoadjuvant Dose-dense EC Followed by ABX With PD-1 for Triple Negative Breast Cancer Patients","source_id_and_acronym":"NCT04418154 - NeoTENNIS","lead_sponsor":"Fudan University","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 negative • ER negative • PGR negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • ER negative • PGR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Loqtorzi (toripalimab-tpzi) • albumin-bound paclitaxel • cyclophosphamide • epirubicin"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 06/09/2020","start_date":" 06/09/2020","primary_txt":" Primary completion: 09/28/2022","primary_completion_date":" 09/28/2022","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-05-21"},{"id":"b2d0e16f-9f16-4b18-afd1-1b771c949f14","acronym":"","url":"https://clinicaltrials.gov/study/NCT05955105","created_at":"2024-05-21T20:33:37.710Z","updated_at":"2024-07-02T16:35:02.295Z","phase":"Phase 1/2","brief_title":"A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies","source_id_and_acronym":"NCT05955105","lead_sponsor":"Innolake Biopharm","biomarkers":" PD-L1 • TMB • MSI • CD8 • CD68","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1 • TMB • MSI • CD8 • CD68"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Loqtorzi (toripalimab-tpzi) • ILB-2109"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 07/25/2023","start_date":" 07/25/2023","primary_txt":" Primary completion: 01/25/2026","primary_completion_date":" 01/25/2026","study_txt":" Completion: 07/24/2026","study_completion_date":" 07/24/2026","last_update_posted":"2024-05-21"},{"id":"0d7726c2-14a5-444d-8b94-705fe08c0ff2","acronym":"","url":"https://clinicaltrials.gov/study/NCT05798845","created_at":"2023-04-05T14:03:20.140Z","updated_at":"2024-07-02T16:35:03.010Z","phase":"Phase 2","brief_title":"The Effect of Toripalimab Plus Radiotherapy in Patients With Operable Stage II-IIIA (N+) Non Small Cell Lung Cancer","source_id_and_acronym":"NCT05798845","lead_sponsor":"Shanghai Chest Hospital","biomarkers":" EGFR • ALK • ROS1","pipe":" | ","alterations":" PD-L1 expression • EGFR mutation • ALK mutation","tags":["EGFR • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • EGFR mutation • ALK mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • Loqtorzi (toripalimab-tpzi)"],"overall_status":"Recruiting","enrollment":" Enrollment 124","initiation":"Initiation: 02/20/2023","start_date":" 02/20/2023","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-05-17"},{"id":"549a7364-24ed-4cb0-a1a5-48fe62ef459e","acronym":"","url":"https://clinicaltrials.gov/study/NCT05804526","created_at":"2023-04-07T13:03:06.963Z","updated_at":"2024-07-02T16:35:07.029Z","phase":"Phase 1/2","brief_title":"A Study of RC88 Combined With Sintilimab for Advanced Solid Tumours","source_id_and_acronym":"NCT05804526","lead_sponsor":"RemeGen Co., Ltd.","biomarkers":" MSLN","pipe":" | ","alterations":" MSLN positive","tags":["MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSLN positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tyvyt (sintilimab) • Loqtorzi (toripalimab-tpzi) • misitatug blivedotin (RC88)"],"overall_status":"Recruiting","enrollment":" Enrollment 82","initiation":"Initiation: 07/19/2023","start_date":" 07/19/2023","primary_txt":" Primary completion: 05/01/2025","primary_completion_date":" 05/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-04-30"},{"id":"5d0bb067-65b0-4094-b54b-a91e3fcb9734","acronym":"CT041-CG4006","url":"https://clinicaltrials.gov/study/NCT03874897","created_at":"2021-03-09T08:59:23.397Z","updated_at":"2024-07-02T16:35:06.986Z","phase":"Phase 1","brief_title":"Chimeric Antigen Receptor T Cells Targeting claudin18.2 in Solid Tumors.","source_id_and_acronym":"NCT03874897 - CT041-CG4006","lead_sponsor":"Peking University","biomarkers":" CLDN18","pipe":"","alterations":" ","tags":["CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Loqtorzi (toripalimab-tpzi) • cyclophosphamide • satricabtagene autoleucel (CT041)"],"overall_status":"Completed","enrollment":" Enrollment 134","initiation":"Initiation: 03/26/2019","start_date":" 03/26/2019","primary_txt":" Primary completion: 03/20/2021","primary_completion_date":" 03/20/2021","study_txt":" Completion: 01/26/2024","study_completion_date":" 01/26/2024","last_update_posted":"2024-04-30"},{"id":"c703229f-ea46-417e-ae6d-490781cb8e12","acronym":"","url":"https://clinicaltrials.gov/study/NCT06151743","created_at":"2023-11-30T21:17:03.568Z","updated_at":"2024-07-02T16:35:06.790Z","phase":"Phase 2","brief_title":"Neoadjuvant PD-1 Inhibitor Combined With Cetuximab and Platinum in Resectable Locally Advanced Hypopharyngeal Carcinoma","source_id_and_acronym":"NCT06151743","lead_sponsor":"Eye \u0026 ENT Hospital of Fudan University","biomarkers":" PD-1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • cisplatin • carboplatin • Loqtorzi (toripalimab-tpzi)"],"overall_status":"Recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 01/18/2024","start_date":" 01/18/2024","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2024-04-30"},{"id":"a264e99a-347f-4737-a295-a9c2c9f14c53","acronym":"","url":"https://clinicaltrials.gov/study/NCT05060471","created_at":"2021-09-29T11:53:44.991Z","updated_at":"2024-07-02T16:35:07.827Z","phase":"Phase 2","brief_title":"PD-1 Blockade Combined With Chemotherapy Followed by Concurrent Immunoradiotherapy for Locally Advanced SCCA Patients","source_id_and_acronym":"NCT05060471","lead_sponsor":"Sun Yat-sen University","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Loqtorzi (toripalimab-tpzi)"],"overall_status":"Enrolling by invitation","enrollment":" Enrollment 27","initiation":"Initiation: 09/08/2021","start_date":" 09/08/2021","primary_txt":" Primary completion: 04/22/2024","primary_completion_date":" 04/22/2024","study_txt":" Completion: 06/30/2024","study_completion_date":" 06/30/2024","last_update_posted":"2024-04-24"},{"id":"ef40256d-bc70-4255-8a24-3750c83e5f0a","acronym":"","url":"https://clinicaltrials.gov/study/NCT04301557","created_at":"2021-01-18T20:51:48.815Z","updated_at":"2024-07-02T16:35:08.054Z","phase":"Phase 2","brief_title":"PD1 Antibody Toripalimab and Chemoradiotherapy for dMMR/MSI-H Locally Advanced Colorectal Cancer","source_id_and_acronym":"NCT04301557","lead_sponsor":"Sun Yat-sen University","biomarkers":" MSI • MSH6 • MSH2","pipe":" | ","alterations":" MSI-H/dMMR","tags":["MSI • MSH6 • MSH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Loqtorzi (toripalimab-tpzi) • capecitabine • oxaliplatin"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 07/31/2020","start_date":" 07/31/2020","primary_txt":" Primary completion: 04/22/2024","primary_completion_date":" 04/22/2024","study_txt":" Completion: 12/30/2024","study_completion_date":" 12/30/2024","last_update_posted":"2024-04-23"}]